Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

Published

Journal Article (Review)

INTRODUCTION: Historically, there were few effective and durable treatments for metastatic melanoma. Recently, mutation based targeted therapies have revolutionized treatment and outcomes for patients with metastatic melanoma. Specifically, inhibitors aimed at BRAF, NRAS, and C-KIT mutations are now commonly used in treatment for patients harboring the specific mutations. Areas covered: A brief review of current BRAF, NRAS, and C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF inhibitor, and masitinib which inhibits C-KIT. Expert opinion: While the 3 novel agents reviewed here have potential for use in melanoma, optimal utilization will occur once a more personalized approach incorporating genomic, proteomic, and immunologic data guides therapeutic decisions.

Full Text

Duke Authors

Cited Authors

  • Turner, MC; Rossfeld, K; Salama, AKS; Tyler, D; Beasley, G

Published Date

  • April 2017

Published In

Volume / Issue

  • 18 / 5

Start / End Page

  • 487 - 495

PubMed ID

  • 28277830

Pubmed Central ID

  • 28277830

Electronic International Standard Serial Number (EISSN)

  • 1744-7666

Digital Object Identifier (DOI)

  • 10.1080/14656566.2017.1299710

Language

  • eng

Conference Location

  • England